Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M14,508Revenue $M751Net Margin (%)-18.9Z-Score9.4
Enterprise Value $M14,499EPS $-0.9Operating Margin %-13.0F-Score5
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-17.8Higher ROA y-yY
Price/Book10.710-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsY
Price/Sales24.05-y EBITDA Growth Rate %0Current Ratio5.2Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-5.7Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-9.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M147ROI % (ttm)-9.2Gross Margin Increase y-yY

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 108.4230%Sold Out0
BMRNJohn Griffin 2014-09-30 Add0.11%$55.78 - $73
($65.82)
$ 108.4265%Add 6.19%2,230,000
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 108.4265%New holding, 3885 sh.3,885
BMRNFrank Sands 2014-06-30 Add0.35%$56.15 - $68.61
($60.38)
$ 108.4280%Add 22.47%11,925,248
BMRNRay Dalio 2014-06-30 Sold Out -0.03%$56.15 - $68.61
($60.38)
$ 108.4280%Sold Out0
BMRNJohn Burbank 2014-06-30 Sold Out -0.01%$56.15 - $68.61
($60.38)
$ 108.4280%Sold Out0
BMRNRay Dalio 2014-03-31 Buy 0.03%$64.99 - $83.28
($73.66)
$ 108.4247%New holding, 48400 sh.48,400
BMRNJohn Burbank 2014-03-31 Buy 0.01%$64.99 - $83.28
($73.66)
$ 108.4247%New holding, 5173 sh.5,173
BMRNJohn Griffin 2013-12-31 Add0.23%$59.3 - $75.09
($67.74)
$ 108.4260%Add 17.71%2,060,000
BMRNFrank Sands 2013-09-30 Reduce-0.2%$58.64 - $78.388
($66.48)
$ 108.4263%Reduce -9.49%10,268,812
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 108.4274%Sold Out0
BMRNFrank Sands 2013-03-31 Add0.24%$49.2 - $62.39
($56.51)
$ 108.4292%Add 10.9%10,951,298
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 108.4292%Reduce -69.03%40,700
BMRNFrank Sands 2012-12-31 Add1.56%$36.78 - $50.17
($45.59)
$ 108.42138%Add 450.74%9,874,728
BMRNDaniel Loeb 2012-12-31 Sold Out -0.79%$36.78 - $50.17
($45.59)
$ 108.42138%Sold Out0
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 108.42138%Reduce -60.99%131,400
BMRNJohn Griffin 2012-12-31 Reduce-0.28%$36.78 - $50.17
($45.59)
$ 108.42138%Reduce -20.09%1,750,000
BMRNJohn Griffin 2012-09-30 Buy 1.4%$37.23 - $43.29
($39.41)
$ 108.42175%New holding, 2190000 sh.2,190,000
BMRNDaniel Loeb 2012-09-30 Buy 0.79%$37.23 - $43.29
($39.41)
$ 108.42175%New holding, 1000000 sh.1,000,000
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 108.42201%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BMRN Frank Sands 2014-12-3112,183,1138.262.6+0.7%
BMRN John Griffin 2014-12-312,230,0001.512.4
BMRN PRIMECAP Management 2014-12-318,016,5185.440.73-0.34%
BMRN Joel Greenblatt 2014-12-31000Sold Out
BMRN Meridian Funds 2013-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIENAIME JEAN JACQUESCEO 2015-01-09Sell2,000$94.1415.17view
BIENAIME JEAN JACQUESCEO 2014-12-24Sell5,000$88.7322.19view
BIENAIME JEAN JACQUESCEO 2014-12-10Sell2,000$9514.13view
LEWIS ALANDirector 2014-12-04Sell7,500$89.920.6view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2014-12-03Sell12,000$91.0119.13view
Mueller BrianVP, Corporate Controller 2014-12-02Sell11,950$90.9119.26view
Mueller BrianVP, Corporate Controller 2014-11-26Sell3,400$88.9721.86view
Davis George EricSVP, General Counsel 2014-11-25Sell20,000$89.7520.8view
BIENAIME JEAN JACQUESCEO 2014-11-25Sell2,000$9020.47view
BIENAIME JEAN JACQUESCEO 2014-11-12Sell1,000$81.5133.01view

Press Releases about BMRN :

    Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 
    BioMarin Pharmaceutical Inc. (BMRN) SVP, CFO Jeffrey H Cooper sells 11,250 Shares Nov 24 2010 

    More From Our Partners
    Company News for February 27, 2015 - Corporate Summary Feb 27 2015 - ZACKS

    More From Other Websites
    Company News for February 27, 2015 - Corporate Summary Feb 27 2015
    Cowen Raises Price Targets on Top Momentum Stocks Feb 27 2015
    Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Feb 26 2015
    Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Feb 26 2015
    Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Feb 26 2015
    Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog Feb 26 2015
    BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Feb 26 2015
    Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Feb 26 2015
    Lightning Round: This group goes higher tomorrow Feb 25 2015
    BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
    BioMarin reports 4Q loss Feb 25 2015
    BioMarin reports 4Q loss Feb 25 2015
    Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today Feb 25 2015
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 25 2015
    BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
    PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer Feb 25 2015
    Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Feb 25 2015
    Q4 2014 Biomarin Pharmaceutical Inc Earnings Release - After Market Close Feb 25 2015
    Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog Feb 24 2015
    Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK